Answers are grounded in this paper and cite their sources.
Cytogenetic abnormalities in Down Syndrome (DS) are unique and emphasise upon the association between chromosome 21 and cancer.DS patients are high risk patients to develop leukemia specifically AMKL-a FAB subtype AML-M7 as compared to any other subtype of AML and ALL.Patients with DS shows GATA mutation and have better outcomes as compared to Non-DS AMKL.Their laboratory and clinical features are unique.Because of the development of uniform treatment protocols, there is an improvement in the clinical outcomes for DS-associated leukemia over the years.In our cytogenetic laboratory, we have studied 3 pediatric DS patients with AMKL.Bone marrow and Peripheral blood lymphocytes were used for conventional cytogenetic and Fluorescence in Situ Hybridization technique.Using standard protocol metaphases achieved and GTG banding was carried out for karyotype analysis.In FISH technique Locus specific Identifier RUNX1T1/RUNX1 probe was used.Trisomy 21 was confirmed in stimulated and unstimulated blood culture and by FISH technique.All patients have better survival with standard induction therapy.The present study highlights the screening of all DS patients and their follow up study to understand the progression to AMKL for tailoring therapy regimen.
No takes yet. Share an insight, caveat, or question.
Trivedi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: